In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on Asia and emerging markets. In the last installment, PharmAsia News looked at the emerging markets strategy of Shire PLC and Mylan NV ([A#28130509015]).
Novo Nordisk AS has blamed poor performance in Japan and Korea, where the company saw sales drop 4% in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?